Your Search Results

Modern risk prediction in TAVI

21 May 2026 – From EuroPCR 2026

This session examines modern risk prediction models in transcatheter aortic valve implantation (TAVI). It presents novel scoring systems, the prognostic significance of cardiac damage extent and progression, and the impact of multivalvular disease, enhancing patient stratification and outcome prediction.

Overcoming complications with intracoronary imaging

21 May 2026 – From EuroPCR 2026

Explore challenging cases of intracoronary imaging complications, highlighting recognition, management, and resolution of complex vascular and mechanical issues encountered during coronary interventions.

How to achieve coronary patency during TAVI

21 May 2026 – From EuroPCR 2026

This session addresses techniques to achieve coronary artery patency during transcatheter aortic valve implantation (TAVI), highlighting advanced procedural approaches and management of high-risk anatomical scenarios.

Sealing the deal: catheter based solutions for aortic disease

21 May 2026 – From EuroPCR 2026

Examine catheter-based solutions for aortic disease management, featuring innovative approaches to preserving branch vessels, managing vascular complications, and repairing challenging aneurysms with endografts and occluders.

RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation

05 Sep 2023

Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.

Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...

Author

Alessandro Sticchi

RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation

Evidence base: current data on TAVI durability and long-term outcomes

22 Jul 2026

This article reviews the current evidence on TAVI durability, focusing on long-term outcomes, device-specific considerations, and the implications for lifetime management strategies.

Author

Tanja Rudolph

Author

Georges El Hachem

Evidence base: current data on durability

SURTAVI: five-year results from a randomized trial of TAVR vs. SAVR in patients at intermediate surgical risk

07 Nov 2021

Although TAVI is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about long-term comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk. P. Redaelli & M. Pighi review the SURTAVI trial...